ProShare Advisors
SNNA

ProShare Advisors’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

ProShare Advisors’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,367
Closed -$154K – 1776
2018
Q3 		$154K Sell
10,367
-376
-3% -$5.97K ﹤0.01% 1634
2018
Q2 		$163K Sell
10,743
-683
-6% -$11.6K ﹤0.01% 1656
2018
Q1 		$215K Sell
11,426
-387
-3% -$6.76K ﹤0.01% 1515
2017
Q4 		$214K Buy
+11,813
New +$250K ﹤0.01% 1607

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's SNNA Position: Q4 2018 in Review

ProShare Advisors sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2018, closing a stake of 10,367 shares — an estimated $154K sold.

ProShare Advisors first reported a position in SNNA in Q4 2017 and held it in 4 quarters. The position peaked at $215K in Q1 2018. 60 funds tracked by Wall St. Rank hold SNNA as of Q4 2018.

  • ProShare Advisors reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • ProShare Advisors sold 10,367 Sienna Biopharmaceuticals, Inc. shares in Q4 2018, an estimated $154K.
  • ProShare Advisors first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
  • ProShare Advisors's Sienna Biopharmaceuticals, Inc. position peaked at $215K in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.